Omeros Co. (NASDAQ:OMER - Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.00 and traded as high as $3.82. Omeros shares last traded at $3.38, with a volume of 429,470 shares.
Analysts Set New Price Targets
Separately, StockNews.com raised shares of Omeros from a "sell" rating to a "hold" rating in a research report on Wednesday, April 3rd.
Check Out Our Latest Stock Analysis on Omeros
Omeros Price Performance
The firm has a market capitalization of $198.73 million, a P/E ratio of -1.80 and a beta of 1.34. The business's 50-day moving average is $3.90 and its 200 day moving average is $3.00.
Hedge Funds Weigh In On Omeros
Hedge funds have recently bought and sold shares of the company. Ameritas Investment Partners Inc. bought a new stake in shares of Omeros during the 2nd quarter valued at approximately $27,000. Farther Finance Advisors LLC bought a new stake in shares of Omeros during the 2nd quarter valued at approximately $33,000. Tower Research Capital LLC TRC grew its holdings in shares of Omeros by 199.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,069 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 5,378 shares during the last quarter. ExodusPoint Capital Management LP bought a new stake in shares of Omeros during the 1st quarter valued at approximately $54,000. Finally, Alliancebernstein L.P. acquired a new stake in Omeros during the 2nd quarter worth approximately $64,000. 48.79% of the stock is owned by institutional investors.
About Omeros
(
Get Free Report)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
See Also
Before you consider Omeros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.
While Omeros currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
